Hm Payson & CO Dexcom Inc Transaction History

Hm Payson & CO

$5.81 Billion
Q3 2024

A detailed history of Hm Payson & CO transactions in Dexcom Inc stock. As of the latest transaction made, Hm Payson & CO holds 1,130 shares of DXCM stock, worth $87,868. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,130

Previous 1,408 19.74%

Holding current value

$87,868

Previous $159,000 52.83%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$64.0 - $116.06 $17,792 - $32,264	-278 Reduced 19.74%	1,130 $75,000
Q2 2024 Aug 13, 2024	SELL	$110.31 - $140.45 $41,035 - $52,247	-372 Reduced 20.9%	1,408 $159,000
Q1 2024 Jun 20, 2024	BUY	$114.22 - $140.1 $11,422 - $14,010	100 Added 5.95%	1,780 $246,000
Q4 2023 Feb 13, 2024	BUY	$75.49 - $124.16 $15,097 - $24,832	200 Added 13.51%	1,680 $208,000
Q3 2023 Nov 06, 2023	BUY	$86.06 - $137.93 $9,982 - $15,999	116 Added 8.5%	1,480 $138,000
Q2 2023 Jul 17, 2023	BUY	$112.47 - $130.98 $22,494 - $26,195	200 Added 17.18%	1,364 $175,000
Q4 2022 Feb 06, 2023	BUY	$84.98 - $122.67 $2,039 - $2,944	24 Added 2.11%	1,164 $131,000
Q2 2022 Aug 15, 2022	BUY	$67.99 - $132.89 $58,131 - $113,620	855 Added 300.0%	1,140 $84,000
Q1 2022 May 12, 2022	BUY	$94.08 - $130.2 $1,411 - $1,952	15 Added 5.56%	285 $146,000
Q4 2021 Feb 15, 2022	SELL	$129.87 - $162.82 $3,896 - $4,884	-30 Reduced 10.0%	270 $145,000
Q4 2020 Mar 10, 2021	SELL	$78.0 - $104.5 $19,656 - $26,334	-252 Reduced 45.65%	300 $111,000
Q3 2020 Dec 21, 2020	BUY	$95.51 - $112.95 $24,068 - $28,463	252 Added 84.0%	552 $228,000
Q1 2020 Jul 01, 2020	BUY	$47.79 - $75.63 $14,337 - $22,689	300 New	300 $81,000

Others Institutions Holding DXCM

# of Institutions

1,013

Shares Held

351M

Call Options Held

5.51M

Put Options Held

5.6M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $30B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

News

Stay updated on Hm Payson & CO with notifications on news.

Account